Key TakeawaysEli Lilly shares set a record high on Tuesday after announcing that clinical trials of tirzepatide, the medicine used in the company’s diabetes drug Mounjaro and injectable weight loss treatment Zepbound, significantly reduced the risk of developing type 2 diabetes in patients. The stock has oscillated within a broadening wedge since early May last year, with an earnings-driven gap on Aug. 8 accelerating recent bullish momentum.Eli Lilly shares may encounter support around $885 and$790, but ru ...